CORC

在结果中检索

CORC

浏览/检索结果: 共11条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Nitrogen-Doped Carbon Nanotube Confined Co-N-x Sites for Selective Hydrogenation of Biomass-Derived Compounds 期刊论文
ADVANCED MATERIALS, 2019, 卷号: 31, 期号: 11, 页码: 8
作者:  Gong, Wanbing;  Lin, Yue;  Chen, Chun;  Al-Mamun, Mohammad;  Lu, Hai-Sheng
收藏  |  浏览/下载：9/0  |  提交时间：2020/07/14
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文
JOURNAL OF HEPATOLOGY, 2019, 卷号: 70
作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun
收藏  |  浏览/下载：57/0  |  提交时间：2019/12/05
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial 期刊论文
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 卷号: 4, 期号: 2
作者:  Li, Jun;  Jia, Jidong;  Hou, Jin Lin;  Mohamed, Rosmawati;  Duan, Zhongping
收藏  |  浏览/下载：44/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：46/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：38/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
Nomogram prediction of individual prognosis of patients with acute-on-chronic hepatitis B liver failure 期刊论文
DIGESTIVE AND LIVER DISEASE, 2019, 卷号: 51, 期号: 3
作者:  Gao, Fangyuan;  Zhang, Qianqian;  Liu, Yao;  Gong, Guozhong;  Mao, Dewen
收藏  |  浏览/下载：27/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：30/0  |  提交时间：2019/12/05
Nomogram prediction of individual prognosis of patients with acute-on-chronic hepatitis B liver failure 期刊论文
Digestive and Liver Disease, 2019, 卷号: Vol.51 No.3, 页码: 425-433
作者:  Fangyuan Gao;  Qianqian Zhang;  Yao Liu;  Guozhong Gong;  Dewen Mao
收藏  |  浏览/下载：60/0  |  提交时间：2019/12/13

©版权所有 ©2017 CSpace - Powered by CSpace